ArticleOncoimmunology2020
IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice.
Article in Oncoimmunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 55 citations in OpenAlex.
- Metabolic Bottlenecks and Opportunities: Reshaping the Tumor Microenvironment for Cancer Immunotherapy.Cells · 2026Review
- Review
- A novel inositol phosphate metabolism signature predicts survival prognosis in low grade glioma.Discover oncology · 2025Article
- Phenotypic stratification of Low-grade Glioma using multimodal MRI via outcome-weighted integrative clustering.BMC neurology · 2025Article
- TCA cycle-derived oncometabolites in cancer and the immune microenvironment.Journal of biomedical science · 2025Review
- Review
- Integrating Multiplex Immunohistochemistry and Machine Learning for Glioma Subtyping and Prognosis Prediction.MedComm · 2025Article
- Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Review
- Constitutive type-1 interferons signaling activity in malignant gliomas.Journal of neuro-oncology · 2024Article
- Systemic and local immunosuppression in glioblastoma and its prognostic significance.Frontiers in immunology · 2024Review
- D-2-hydroxyglutarate regulates human brain vascular endothelial cell proliferation and barrier function.Journal of neuropathology and experimental neurology · 2023Article
- An N6-methyladenosine regulation- and mRNAsi-related prognostic index reveals the distinct immune microenvironment and immunotherapy responses in lower-grade glioma.BMC bioinformatics · 2023Article
- Mechanisms driving the immunoregulatory function of cancer cells.Nature reviews. Cancer · 2023Review
- Dendritic cell vaccine of gliomas: challenges from bench to bed.Frontiers in immunology · 2023Review
- Association of RNA-modification "writer" genes with prognosis and response to immunotherapy in patients with low-grade glioma.PloS one · 2023Article
- Cancer vaccine strategies for the treatment of diffusely infiltrating gliomas.Therapeutic advances in vaccines and immunotherapy · 2023Review
- New insights into the Immune TME of adult-type diffuse gliomas.Current opinion in neurology · 2022Review
- Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma.Neuroscience bulletin · 2022Review
- Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity.Journal of hematology & oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
Abstract
The metabolic gene isocitrate dehydrogenase 1 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.